Navigation Links
Landmark Patents Issued for ViewRay Technology
Date:5/18/2011

CLEVELAND, May 18, 2011 /PRNewswire/ -- The core technology of ViewRay™, Inc., a unique combination of magnetic resonance imaging (MRI) and radiotherapy technologies, has been issued landmark patents in the United States and Europe. ViewRay, a privately held medical device company, holds the exclusive worldwide license for the technology from the University of Florida. The cancer treatment technology was invented by company founder James F. Dempsey, PhD, while he was a member of the radiation oncology faculty at the University of Florida.

The patented technology is key to ViewRay's new radiation therapy system, which is being designed to capture soft-tissue images continuously during treatment. "The technology is intended to enable clinicians to see precisely where the radiation is being delivered, as it's being delivered," said Dempsey, now ViewRay's chief scientific officer. "Our goal is to allow clinicians to know, to control, and to optimize the dose to the patient." Broadly covering both the medical device and the method of implementation, the patents acknowledge the unique combination of simultaneous MRI and radioisotope irradiation.

The University of Florida encouraged Dempsey to bring his invention to the marketplace, where it could begin to benefit cancer patients, and ViewRay was formed. The ViewRay System, now in the late stages of development, is currently available only as a non-human use research system. The company is working to secure FDA clearance for commercial distribution of the system for clinical use. "These are landmark patents," said David L. Day, director of the University of Florida Office of Technology Licensing. "We believe they are important pieces of intellectual property that can provide significant competitive advantages in the radiation therapy industry."

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. Using MRI-guided radiotherapy, the ViewRay System is being designed to provide continuous soft-tissue imaging during treatment. The system is being developed so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

ViewRay is a trademark of ViewRay, Inc.

About the University of Florida

Transferring technology to the marketplace is an important responsibility for the University of Florida (UF), one of the nation's leading public research universities. Since 1985, the UF Office of Technology Licensing has helped to transfer hundreds of technologies from university laboratories to private industry. In the marketplace, these technologies improve the lives of millions, benefiting society and creating jobs. For more information, visit http://www.research.ufl.edu/otl/.


'/>"/>
SOURCE ViewRay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
2. Data From Landmark Clinical Trial of Abbotts MitraClip® System Demonstrate Durable Clinical Benefits for Patients With Mitral Regurgitation Two Years After Treatment
3. Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine
4. Landmark National Survey Conducted by Harris Interactive® Sheds Light on Hidden Problem of Heavy Monthly Periods
5. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
6. US HIFU to Fund Landmark Investigation of Focal Therapy for Prostate Cancer
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
9. ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis
10. Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... ... Konur, CEO of Cardiovascular Institute of the South announced today that Dr. Robert ... live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , This ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and ... to the impact our aging population has on communities and resources. Aging Life Care ... for and face age-related challenges. , Aging Life Care is a holistic, client-centered ...
(Date:5/5/2016)... Chicago, Illinois (PRWEB) , ... May 05, 2016 ... ... published its “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit ... as a “tobacco product,” apply to all vaping products that entered the market ...
(Date:5/5/2016)... ... ... from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper ... Mountain Bike Camp, hosted in conjunction with WTB and Cannondale in ... who’ll share pro tips with the injured veterans as they rip down some of the ...
(Date:5/5/2016)... , ... May 05, 2016 , ... LELO ... self-love. Every day, LELO fans reach out via email, social media and on the ... upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , While some methods ...
Breaking Medicine News(10 mins):